

Genomic analyses of gynaecologic carcinosarcomas reveal chromatin remodelling genes

Nature Communications

5, 5006

DOI: [10.1038/ncomms6006](https://doi.org/10.1038/ncomms6006)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Molecular Pathology and Cytogenetics of Endometrial Carcinoma, Carcinosarcoma, and Uterine Sarcomas. <i>Current Clinical Oncology</i> , 2015, , 85-103.	0.0	0
2	SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. <i>Cell Reports</i> , 2015, 13, 1183-1193.	2.9	55
3	Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft. <i>PLoS ONE</i> , 2015, 10, e0126867.	1.1	24
4	In-depth molecular profiling of the biphasic components of uterine carcinosarcomas. <i>Journal of Pathology: Clinical Research</i> , 2015, 1, 173-185.	1.3	70
5	Coexistent ARID1A and PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. <i>Nature Communications</i> , 2015, 6, 6118.	5.8	247
6	The cancer COMPASS: navigating the functions of MLL complexes in cancer. <i>Cancer Genetics</i> , 2015, 208, 178-191.	0.2	122
7	Histone Methylation Modifiers in Medical Therapeutics. , 2016, , 705-729.		1
8	A Role for the Chromatin Remodeling Factor <i>BAZ1A</i> in Neurodevelopment. <i>Human Mutation</i> , 2016, 37, 964-975.	1.1	29
9	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. <i>Leukemia</i> , 2016, 30, 1672-1681.	3.3	99
10	Molecular Pathology. <i>Surgical Pathology Clinics</i> , 2016, 9, 405-426.	0.7	17
11	Genetic Investigation of Uterine Carcinosarcoma: Case Report and Cohort Analysis. <i>Cancer Control</i> , 2016, 23, 61-66.	0.7	14
12	Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor. <i>Human Pathology</i> , 2016, 53, 159-167.	1.1	1
13	Uterine adenosarcomas are mesenchymal neoplasms. <i>Journal of Pathology</i> , 2016, 238, 381-388.	2.1	94
14	Epigenomic regulation of oncogenesis by chromatin remodeling. <i>Oncogene</i> , 2016, 35, 4423-4436.	2.6	86
15	A panoply of errors: polymerase proofreading domain mutations in cancer. <i>Nature Reviews Cancer</i> , 2016, 16, 71-81.	12.8	292
16	Pharmacological Inhibition of the Histone Lysine Demethylase KDM1A Suppresses the Growth of Multiple Acute Myeloid Leukemia Subtypes. <i>Cancer Research</i> , 2016, 76, 1975-1988.	0.4	89
17	Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2017, 31, 340-349.	3.3	33
18	Genomic insights in gynecologic cancer. <i>Current Problems in Cancer</i> , 2017, 41, 8-36.	1.0	13

#	ARTICLE	IF	CITATIONS
19	The NF1 gene in tumor syndromes and melanoma. <i>Laboratory Investigation</i> , 2017, 97, 146-157.	1.7	144
20	Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. <i>Neoplasia</i> , 2017, 19, 100-111.	2.3	27
21	SETting the Stage for Cancer Development: SETD2 and the Consequences of Lost Methylation. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026468.	2.9	60
22	The importance of regulatory ubiquitination in cancer and metastasis. <i>Cell Cycle</i> , 2017, 16, 634-648.	1.3	134
23	The Relationship Between DOT1L, Histone H3 Methylation, and Genome Stability in Cancer. <i>Current Molecular Biology Reports</i> , 2017, 3, 18-27.	0.8	4
24	PBRM1 loss is a late event during the development of cholangiocarcinoma. <i>Histopathology</i> , 2017, 71, 375-382.	1.6	18
25	Next-Generation Sequencing. <i>Advances in Experimental Medicine and Biology</i> , 2017, 943, 119-148.	0.8	54
26	Structural insights into the function of ZRANB3 in replication stress response. <i>Nature Communications</i> , 2017, 8, 15847.	5.8	41
27	miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas. <i>Scientific Reports</i> , 2017, 7, 3614.	1.6	22
28	Establishment and characterization of uterine sarcoma and carcinosarcoma patient-derived xenograft models. <i>Gynecologic Oncology</i> , 2017, 146, 538-545.	0.6	16
29	Integrated Molecular Characterization of Uterine Carcinosarcoma. <i>Cancer Cell</i> , 2017, 31, 411-423.	7.7	309
30	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. <i>Journal of Thoracic Oncology</i> , 2017, 12, 932-942.	0.5	129
31	Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors. <i>Nature Communications</i> , 2017, 8, 1221.	5.8	75
32	Aberrant chromatin remodeling in gynecological cancer (Review). <i>Oncology Letters</i> , 2017, 14, 5107-5113.	0.8	8
33	Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nature Medicine</i> , 2017, 23, 1046-1054.	15.2	145
34	Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups. <i>Modern Pathology</i> , 2017, 30, 1748-1759.	2.9	72
35	NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma. <i>Scientific Reports</i> , 2017, 7, 17064.	1.6	67
36	EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1172.	1.8	73

#	ARTICLE	IF	CITATIONS
37	Endometrial Cancer Genomics. , 2017, , 199-227.		0
38	Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. <i>Cancer Medicine</i> , 2018, 7, 616-625.	1.3	5
39	Loss of ARID1A Expression Correlates With Tumor Differentiation and Tumor Progression Stage in Pancreatic Ductal Adenocarcinoma. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303461875447.	0.8	26
40	Optimised ARID1A immunohistochemistry is an accurate predictor of <i>ARID1A</i> mutational status in gynaecological cancers. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 154-166.	1.3	51
41	Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma. <i>Oncologist</i> , 2018, 23, 518-523.	1.9	40
42	Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883401774604.	1.4	11
43	The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. <i>Journal of Pathology</i> , 2018, 244, 538-549.	2.1	172
44	Survey of gynecological carcinosarcomas in families with breast and ovarian cancer predisposition. <i>Cancer Genetics</i> , 2018, 221, 38-45.	0.2	4
45	Genomic profiling identifies <i>GPC5</i> amplification in association with sarcomatous transformation in a subset of uterine carcinosarcomas. <i>Journal of Pathology: Clinical Research</i> , 2018, 4, 69-78.	1.3	9
46	Uterine function in the mouse requires speckle-type poz protein. <i>Biology of Reproduction</i> , 2018, 98, 856-869.	1.2	10
47	The <i>FOXA2</i> transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. <i>Cancer</i> , 2018, 124, 65-73.	2.0	27
48	Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition. <i>Journal of Clinical Oncology</i> , 2018, 36, 210-216.	0.8	62
49	Pretreatment Identification of Head and Neck Cancer Nodal Metastasis and Extranodal Extension Using Deep Learning Neural Networks. <i>Scientific Reports</i> , 2018, 8, 14036.	1.6	139
50	Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. <i>Gynecologic Oncology</i> , 2018, 151, 243-249.	0.6	11
51	Genetic Alterations of TRAF Proteins in Human Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 2111.	2.2	67
52	In vitro effects of <i>FBXW7</i> mutation in serous endometrial cancer: Increased levels of potentially druggable proteins and sensitivity to S1 and dinaciclib. <i>Molecular Carcinogenesis</i> , 2018, 57, 1445-1457.	1.3	12
53	Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1). <i>Journal of Ovarian Research</i> , 2018, 11, 58.	1.3	5
54	Voxel size and gray level normalization of CT radiomic features in lung cancer. <i>Scientific Reports</i> , 2018, 8, 10545.	1.6	150

#	ARTICLE	IF	CITATIONS
55	Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma. <i>BMC Cancer</i> , 2018, 18, 251.	1.1	18
56	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 16.	0.7	123
57	Epigenetic Dysregulation at the Crossroad of Women's Cancer. <i>Cancers</i> , 2019, 11, 1193.	1.7	11
58	Clinical actionability of molecular targets in endometrial cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 510-521.	12.8	261
59	Molecular Basis of Tumor Heterogeneity in Endometrial Carcinosarcoma. <i>Cancers</i> , 2019, 11, 964.	1.7	54
60	Misidentification of MLL3 and other mutations in cancer due to highly homologous genomic regions. <i>Leukemia and Lymphoma</i> , 2019, 60, 3132-3137.	0.6	5
61	Molecular profiling and molecular classification of endometrioid ovarian carcinomas. <i>Gynecologic Oncology</i> , 2019, 154, 516-523.	0.6	62
62	Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. <i>Nature Communications</i> , 2019, 10, 4965.	5.8	82
63	Unique Molecular Features in High-Risk Histology Endometrial Cancers. <i>Cancers</i> , 2019, 11, 1665.	1.7	12
64	New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach. <i>Cells</i> , 2019, 8, 584.	1.8	25
65	Sarcomatoid carcinomas of the gallbladder: clinicopathologic characteristics. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 59-66.	1.4	16
66	Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 5584-5594.	3.2	80
67	Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. <i>Cell Reports</i> , 2019, 27, 1781-1793.e4.	2.9	102
68	Systematic characterization of germline variants from the DiscovEHR study endometrial carcinoma population. <i>BMC Medical Genomics</i> , 2019, 12, 59.	0.7	2
69	Structural Insights into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants. <i>Journal of Molecular Biology</i> , 2019, 431, 2213-2221.	2.0	12
70	MLH1 promoter hypermethylation in uterine carcinosarcoma rarely coexists with TP53 mutation. <i>Wspolczesna Onkologia</i> , 2019, 23, 202-207.	0.7	2
71	Endometrial Cancers in <i>BRCA1</i> or <i>BRCA2</i> Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	1.5	19
72	Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities. <i>Cancer</i> , 2019, 125, 1185-1199.	2.0	36

#	ARTICLE	IF	CITATIONS
73	Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa. <i>Histopathology</i> , 2019, 74, 638-650.	1.6	11
74	Molecular Genetics of Endometrial Carcinoma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2019, 14, 339-367.	9.6	163
75	Genomic Applications in Gynecologic Malignancies. , 2019, , 445-469.		0
76	Coexistence of BRAF V600E and TERT Promoter Mutations in Low-grade Serous Carcinoma of Ovary Recurring as Carcinosarcoma in a Lymph Node. <i>International Journal of Gynecological Pathology</i> , 2019, 38, 386-392.	0.9	2
77	Genomics of gynaecological carcinosarcomas and future treatment options. <i>Seminars in Cancer Biology</i> , 2020, 61, 110-120.	4.3	12
78	Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease. <i>International Journal of Gynecological Pathology</i> , 2020, 39, 305-312.	0.9	3
79	Synovial Sarcoma of the Female Genital Tract. <i>American Journal of Surgical Pathology</i> , 2020, 44, 1487-1495.	2.1	11
80	Immunohistochemical evaluation of mismatch repair proteins and p53 expression in extrauterine carcinosarcoma/sarcomatoid carcinoma. <i>Wspolczesna Onkologia</i> , 2020, 24, 1-4.	0.7	5
81	Time for remodeling: SNF2-family DNA translocases in replication fork metabolism and human disease. <i>DNA Repair</i> , 2020, 95, 102943.	1.3	25
82	Replication Fork Remodeling and Therapy Escape in DNA Damage Response-Deficient Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 670.	1.3	13
83	Identification of the Mutational Landscape of Gynecological Malignancies. <i>Journal of Cancer</i> , 2020, 11, 4870-4883.	1.2	11
84	The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas. <i>Molecular Oncology</i> , 2021, 15, 1024-1039.	2.1	21
85	Is the Oncological Outcome of Early Stage Uterine Carcinosarcoma Different from That of Grade 3 Endometrioid Adenocarcinoma?. <i>Oncology Research and Treatment</i> , 2021, 44, 43-51.	0.8	0
86	Immunohistochemical Markers With Potential Diagnostic, Prognostic, and Therapeutic Significance in Uterine Carcinosarcoma: A Clinicopathologic Study of 43 Cases. <i>International Journal of Gynecological Pathology</i> , 2021, 40, 84-93.	0.9	11
87	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. , 2021, , 1-23.		0
88	Recurrent ZNF83-E293V Mutation Promotes Bladder Cancer Progression through the NF- κ B Pathway via Transcriptional Dysregulation of S100A8. <i>Molecular Therapy</i> , 2021, 29, 275-290.	3.7	8
89	A pilot study of radiomics signature based on biparametric MRI for preoperative prediction of extrathyroidal extension in papillary thyroid carcinoma. <i>Journal of X-Ray Science and Technology</i> , 2021, 29, 171-183.	0.7	1
90	Histomolecular features of high-grade endometrial cancers. <i>Minerva Medica</i> , 2021, 112, 20-30.	0.3	3

#	ARTICLE	IF	CITATIONS
91	HDAC Inhibition Induces Cell Cycle Arrest and Mesenchymal-Epithelial Transition in a Novel Pleural-Effusion Derived Uterine Carcinosarcoma Cell Line. <i>Pathology and Oncology Research</i> , 2021, 27, 636088.	0.9	5
93	Genetic characterisation of adult primary pleomorphic uterine rhabdomyosarcoma and comparison with uterine carcinosarcoma. <i>Histopathology</i> , 2021, 79, 176-186.	1.6	4
94	Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer. <i>Gynecologic Oncology</i> , 2021, 161, 535-544.	0.6	16
95	Predictive and Prognostic Value of Microsatellite Instability in Gynecologic Cancer (Endometrial and) Tj ETQq1 1 0.784314 rgBJ /Over	1.7	22
96	Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms. <i>Journal of Human Genetics</i> , 2021, 66, 853-868.	1.1	5
97	Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1038-1046.	2.1	12
98	Genomic Analyses of Metaplastic or Sarcomatoid Carcinomas From Different Organs Revealed Frequent Mutations in KMT2D. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 688692.	1.6	4
99	Uterine carcinosarcomas: From pathology to practice. <i>Gynecologic Oncology</i> , 2021, 162, 235-241.	0.6	14
100	Rhabdomyoblasts masquerading as histiocytes: A diagnostic pitfall. <i>Diagnostic Cytopathology</i> , 2021, 49, 1056-1058.	0.5	0
101	Two Components of Variant Profiles in Primary Vaginal Carcinosarcoma via Next-Generation Sequencing and a Literature Review. <i>International Journal of Surgical Pathology</i> , 2021, , 106689692110379.	0.4	1
102	Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature. <i>Diagnostics</i> , 2021, 11, 199.	1.3	24
103	Histone methylation modifiers in medical therapeutics. , 2021, , 693-720.		0
104	Fbxw7 is a driver of uterine carcinosarcoma by promoting epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 25880-25890.	3.3	47
105	Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas. <i>JCI Insight</i> , 2017, 2, .	2.3	15
106	Targeting the TGF β 2 pathway in uterine carcinosarcoma. <i>Cell Stress</i> , 2020, 4, 252-260.	1.4	7
107	DDR2 overexpression in urothelial carcinoma indicates an unfavorable prognosis: a large cohort study. <i>Oncotarget</i> , 2016, 7, 78918-78931.	0.8	11
108	Genetic landscape of extreme responders with anaplastic oligodendroglioma. <i>Oncotarget</i> , 2017, 8, 35523-35531.	0.8	8
109	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. <i>Oncotarget</i> , 2017, 8, 84579-84594.	0.8	23

#	ARTICLE	IF	CITATIONS
110	Molecular characterization of carcinosarcomas arising in the uterus and ovaries. <i>Oncotarget</i> , 2019, 10, 3614-3624.	0.8	9
111	Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas. <i>Oncotarget</i> , 2020, 11, 560-570.	0.8	32
112	Prognostic role and implications of mutation status of tumor suppressor gene ARID1A in cancer: a systematic review and meta-analysis. <i>Oncotarget</i> , 2015, 6, 39088-39097.	0.8	67
113	GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 62-76.	1.5	14
114	Molecular Pathology of Uterine Carcinosarcoma. <i>Molecular Pathology Library</i> , 2017, , 155-167.	0.1	0
119	Rare Peritoneal Tumours: Histopathological Diagnosis and Patterns of Peritoneal Dissemination. , 2020, , 181-228.		0
121	Mutational landscape implicates epithelial-mesenchymal transition gene TGF- β 2 mutations for uterine carcinosarcoma after adjuvant tamoxifen therapy for breast carcinoma. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 996-1002.	0.5	0
122	SPOP and cancer: a systematic review. <i>American Journal of Cancer Research</i> , 2020, 10, 704-726.	1.4	15
123	Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. , 2021, 9, e003156.		6
124	Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer. <i>Genome Medicine</i> , 2022, 14, 3.	3.6	16
125	CDKN1A/p21, RB1, ARID1A, FLC, and HRNR mutation patterns provide insights into urinary tract environmental exposure carcinogenesis and potential treatment strategies. <i>American Journal of Cancer Research</i> , 2021, 11, 5452-5471.	1.4	2
126	The oncogenic fusion landscape in pediatric CNS neoplasms. <i>Acta Neuropathologica</i> , 2022, 143, 427-451.	3.9	22
127	Panel Informativity Optimizer. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 697-709.	1.2	2
128	A novel SNF2 ATPase complex in <i>Trypanosoma brucei</i> with a role in H2A.Z-mediated chromatin remodelling. <i>PLoS Pathogens</i> , 2022, 18, e1010514.	2.1	7
130	Molecular Characterizations of Gynecologic Carcinosarcomas: A Focus on the Immune Microenvironment. <i>Cancers</i> , 2022, 14, 4465.	1.7	0
131	Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. <i>Cancer Research</i> , 2022, 82, 4457-4473.	0.4	7
133	Leveraging the replication stress response to optimize cancer therapy. <i>Nature Reviews Cancer</i> , 2023, 23, 6-24.	12.8	33
134	Identification of alternative transcripts of NSD1 gene in Sotos Syndrome patients and healthy subjects. <i>Gene</i> , 2023, 851, 146970.	1.0	3

#	ARTICLE	IF	CITATIONS
135	A Hypoxia Molecular Signature-Based Prognostic Model for Endometrial Cancer Patients. International Journal of Molecular Sciences, 2023, 24, 1675.	1.8	2
136	Other Carcinomas and Undifferentiated Carcinoma, Pathology of the Ovary. Encyclopedia of Pathology, 2022, , 1-7.	0.0	0
137	Molecular typing guiding treatment and prognosis of endometrial cancer. Gynecology and Obstetrics Clinical Medicine, 2023, 3, 7-17.	0.2	1
147	Other Carcinomas and Undifferentiated Carcinoma, Pathology of the Ovary. Encyclopedia of Pathology, 2023, , 471-476.	0.0	0
148	Molecular profile of bladder cancer progression to clinically aggressive subtypes. Nature Reviews Urology, 0, , .	1.9	0